JP2007527240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007527240A5 JP2007527240A5 JP2007501881A JP2007501881A JP2007527240A5 JP 2007527240 A5 JP2007527240 A5 JP 2007527240A5 JP 2007501881 A JP2007501881 A JP 2007501881A JP 2007501881 A JP2007501881 A JP 2007501881A JP 2007527240 A5 JP2007527240 A5 JP 2007527240A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- sirna
- shrna
- protein
- ige
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 105
- 108091030071 RNAI Proteins 0.000 claims 46
- 230000009368 gene silencing by RNA Effects 0.000 claims 46
- 108020004459 Small interfering RNA Proteins 0.000 claims 43
- 108091027967 Small hairpin RNA Proteins 0.000 claims 40
- 239000004055 small Interfering RNA Substances 0.000 claims 40
- 108090000623 proteins and genes Proteins 0.000 claims 34
- 102000004169 proteins and genes Human genes 0.000 claims 34
- 239000002773 nucleotide Substances 0.000 claims 25
- 125000003729 nucleotide group Chemical group 0.000 claims 25
- 239000003795 chemical substances by application Substances 0.000 claims 17
- 201000010099 disease Diseases 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 17
- 208000001718 Immediate Hypersensitivity Diseases 0.000 claims 12
- 239000013598 vector Substances 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 9
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 8
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 8
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 8
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 8
- 230000001404 mediated effect Effects 0.000 claims 8
- 230000028327 secretion Effects 0.000 claims 8
- 230000008685 targeting Effects 0.000 claims 8
- 102000002627 4-1BB Ligand Human genes 0.000 claims 7
- 108010082808 4-1BB Ligand Proteins 0.000 claims 7
- 101150013553 CD40 gene Proteins 0.000 claims 7
- 102100035793 CD83 antigen Human genes 0.000 claims 7
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 7
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 7
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 claims 7
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 7
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 7
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims 7
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims 7
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 7
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 7
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 claims 7
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 claims 7
- 102000004473 OX40 Ligand Human genes 0.000 claims 7
- 108010042215 OX40 Ligand Proteins 0.000 claims 7
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 7
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 7
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims 7
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims 7
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 7
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 7
- 102100027010 Toll-like receptor 1 Human genes 0.000 claims 7
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 7
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims 7
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims 7
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims 7
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 7
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 7
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims 7
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 7
- 230000004048 modification Effects 0.000 claims 7
- 238000012986 modification Methods 0.000 claims 7
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 238000013518 transcription Methods 0.000 claims 7
- 230000035897 transcription Effects 0.000 claims 7
- -1 ICOS Proteins 0.000 claims 6
- 230000006052 T cell proliferation Effects 0.000 claims 6
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 206010039085 Rhinitis allergic Diseases 0.000 claims 5
- 208000027418 Wounds and injury Diseases 0.000 claims 5
- 201000010105 allergic rhinitis Diseases 0.000 claims 5
- 208000006673 asthma Diseases 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 5
- 230000006378 damage Effects 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 210000003630 histaminocyte Anatomy 0.000 claims 5
- 208000014674 injury Diseases 0.000 claims 5
- 102100038006 High affinity immunoglobulin epsilon receptor subunit alpha Human genes 0.000 claims 4
- 101710128966 High affinity immunoglobulin epsilon receptor subunit alpha Proteins 0.000 claims 4
- 108091081021 Sense strand Proteins 0.000 claims 4
- 239000000443 aerosol Substances 0.000 claims 4
- 201000009961 allergic asthma Diseases 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 210000004241 Th2 cell Anatomy 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 229920006317 cationic polymer Polymers 0.000 claims 3
- 230000036755 cellular response Effects 0.000 claims 3
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 3
- 239000007922 nasal spray Substances 0.000 claims 3
- 229940097496 nasal spray Drugs 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000009261 transgenic effect Effects 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 1
- 108020004394 Complementary RNA Proteins 0.000 claims 1
- 229920002873 Polyethylenimine Polymers 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 102000014450 RNA Polymerase III Human genes 0.000 claims 1
- 108010078067 RNA Polymerase III Proteins 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 102000002689 Toll-like receptor Human genes 0.000 claims 1
- 108020000411 Toll-like receptor Proteins 0.000 claims 1
- 108700009124 Transcription Initiation Site Proteins 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 208000037883 airway inflammation Diseases 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003184 complementary RNA Substances 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 229940124447 delivery agent Drugs 0.000 claims 1
- 239000005547 deoxyribonucleotide Substances 0.000 claims 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 1
- 238000011161 development Methods 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000004199 lung function Effects 0.000 claims 1
- 208000037891 myocardial injury Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims 1
- 108010011110 polyarginine Proteins 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000001018 virulence Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54907004P | 2004-03-01 | 2004-03-01 | |
| PCT/US2005/006445 WO2005085443A2 (en) | 2004-03-01 | 2005-03-01 | Rnai-based therapeutics for allergic rhinitis and asthma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007527240A JP2007527240A (ja) | 2007-09-27 |
| JP2007527240A5 true JP2007527240A5 (enExample) | 2008-03-21 |
Family
ID=34919432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007501881A Pending JP2007527240A (ja) | 2004-03-01 | 2005-03-01 | アレルギー性鼻炎および喘息のためのＲＮＡｉベースの治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20060058255A1 (enExample) |
| EP (1) | EP1737956A2 (enExample) |
| JP (1) | JP2007527240A (enExample) |
| CA (1) | CA2558262A1 (enExample) |
| WO (1) | WO2005085443A2 (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005007623A2 (en) * | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| DE102004010547A1 (de) * | 2004-03-03 | 2005-11-17 | Beiersdorf Ag | Oligoribonukleotide zur Behandlung von irritativen und/oder entzündlichen Hauterscheinungen durch RNA-Interferenz |
| TW200808360A (en) * | 2006-04-13 | 2008-02-16 | Alcon Mfg Ltd | RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions |
| WO2008028085A2 (en) * | 2006-08-30 | 2008-03-06 | The Board Of Trustees Of The University Of Illinois | Modulation of mlck-l expression and uses thereof |
| AU2007324128B2 (en) | 2006-10-10 | 2013-10-10 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations |
| DE102006050655A1 (de) * | 2006-10-24 | 2008-04-30 | Halmon Beheer B.V. | Pharmazeutische Zusammensetzung zur Behandlung allergischer Erkrankungen |
| WO2008091680A2 (en) * | 2007-01-25 | 2008-07-31 | The General Hospital Corporation | Methods for controlling stem cell differentiation |
| EP1953228A1 (en) * | 2007-02-05 | 2008-08-06 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Method to diminish cd83 expression in monocyte-derived dendritic cells, t-cells and b-cells by RNAi |
| WO2008109558A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tlr gene expression and uses thereof |
| JP2010527914A (ja) * | 2007-04-26 | 2010-08-19 | クォーク ファーマシューティカルズ インコーポレーティッド | 呼吸器系への抑制性核酸分子の治療的送達 |
| EP2155889A4 (en) * | 2007-05-25 | 2010-06-16 | Centocor Ortho Biotech Inc | TOLL RECEPTOR 3 MODULATORS AND USES THEREOF |
| US20100326218A1 (en) * | 2007-09-27 | 2010-12-30 | Michael Boeckh | Identifying a subject with an increased risk of invasive mold infection |
| WO2009137505A2 (en) * | 2008-05-05 | 2009-11-12 | University Of Louisville Research Foundation, Inc. | Anti-inflammatory mirnas and uses therefor |
| US20100047188A1 (en) * | 2008-08-04 | 2010-02-25 | Idera Pharmaceuticals, Inc. | Modulation of toll-like receptor 8 expression by antisense oligonucleotides |
| WO2010028367A1 (en) * | 2008-09-05 | 2010-03-11 | The Research Foundation Of State University Of New York | Gold nanorod-sirna complexes and methods of using same |
| EP2342340A1 (en) | 2008-09-22 | 2011-07-13 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
| WO2010045659A1 (en) | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| CN102388139A (zh) * | 2008-11-04 | 2012-03-21 | 艾德拉药物股份有限公司 | 通过反义寡核苷酸来调制Toll样受体5表达 |
| US8435961B2 (en) * | 2009-06-26 | 2013-05-07 | Massachusetts Institute Of Technology | Methods and compositions for increasing the activity of inhibitory RNA |
| WO2010151664A2 (en) | 2009-06-26 | 2010-12-29 | Massachusetts Institute Of Technology | Compositions and methods for treating cancer and modulating stress granule formation |
| US8268550B2 (en) * | 2009-06-26 | 2012-09-18 | Massachusetts Institute Of Technology | Compositions and methods for identification of PARP function, inhibitors, and activators |
| CN102639700A (zh) | 2009-09-30 | 2012-08-15 | 哈佛大学校长及研究员协会 | 通过调节自噬增强基因产物调节自噬的方法 |
| WO2011116371A2 (en) * | 2010-03-19 | 2011-09-22 | The Administrators Of The Tulane Educational Fund | Polyplex gene delivery vectors |
| CA2794189C (en) | 2010-03-24 | 2022-01-11 | Rxi Pharmaceuticals Corporation | Rna interference in dermal and fibrotic indications |
| WO2012112245A1 (en) | 2011-02-14 | 2012-08-23 | Beth Israel Deaconess Medical Center, Inc. | Modulation of phosphatidylinositol-5-phosphate-4-kinase activity |
| US9796979B2 (en) | 2011-03-03 | 2017-10-24 | Quark Pharmaceuticals Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
| EP2681314B1 (en) | 2011-03-03 | 2017-11-01 | Quark Pharmaceuticals, Inc. | Compositions and methods for treating lung disease and injury |
| AU2012223366B2 (en) * | 2011-03-03 | 2017-02-23 | Quark Pharmaceuticals, Inc. | Oligonucleotide modulators of the toll-like receptor pathway |
| WO2013174692A1 (en) * | 2012-05-22 | 2013-11-28 | Ruprecht-Karls-Universität Heidelberg | Therapeutic micro rna targets in chronic pulmonary diseases |
| WO2016134422A1 (en) * | 2015-02-26 | 2016-09-01 | Prince Henry's Institute Of Medical Research Trading As The Hudson Institute Of Medical Research | A method of treatment |
| US11980663B2 (en) | 2015-07-08 | 2024-05-14 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| IL297238B2 (en) | 2016-01-15 | 2024-08-01 | American Gene Tech Int Inc | Methods and preparations for gamma-delta T-cell activation |
| WO2017136435A1 (en) | 2016-02-01 | 2017-08-10 | The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health | Compounds for modulating fc-epsilon-ri-beta expression and uses thereof |
| JP7153332B2 (ja) | 2016-02-08 | 2022-10-14 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | Ｈｉｖワクチン接種および免疫療法 |
| ES2911448T3 (es) | 2016-03-09 | 2022-05-19 | American Gene Tech Int Inc | Vectores combinados y métodos para el tratamiento del cáncer |
| WO2017213697A1 (en) | 2016-06-08 | 2017-12-14 | American Gene Technologies International Inc. | Non-integrating viral delivery system and methods related thereto |
| CA3028982A1 (en) | 2016-07-08 | 2018-01-11 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
| WO2018017882A1 (en) | 2016-07-21 | 2018-01-25 | American Gene Technologies International Inc. | Viral vectors for treating parkinson's disease |
| WO2018170765A1 (zh) * | 2017-03-22 | 2018-09-27 | 深圳市博奥康生物科技有限公司 | Imd16基因的rna干涉载体及其应用 |
| WO2018170763A1 (zh) * | 2017-03-22 | 2018-09-27 | 深圳市博奥康生物科技有限公司 | ILA 基因的 RNAi 表达载体及其构建方法和应用 |
| US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| US12559769B2 (en) | 2017-06-16 | 2026-02-24 | American Gene Technologies International Inc. | Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells |
| EP3746124A4 (en) | 2018-01-30 | 2021-10-27 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| US12473334B2 (en) | 2018-10-17 | 2025-11-18 | Dana-Farber Cancer Institute, Inc. | SWI/SNF family chromatin remodeling complexes and uses thereof |
| EP3876952A4 (en) | 2018-11-05 | 2022-08-24 | American Gene Technologies International Inc. | VECTOR SYSTEM FOR EXPRESSING REGULATORY RNA |
| EP3894559A4 (en) | 2018-12-03 | 2023-04-05 | Triplet Therapeutics, Inc. | METHODS OF TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS RELATED TO MLH3 ACTIVITY |
| JP2022515744A (ja) | 2018-12-20 | 2022-02-22 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | Ｋｃｎｔ１関連障害の治療のための組成物及び方法 |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| EP4054639A4 (en) | 2019-11-08 | 2025-04-30 | North Carolina State University | EXON SKIPPING OF FC-EPSILON-RI-BETA AND MS4A6A IN COMBINATION FOR THE TREATMENT OF ALLERGIC DISEASES |
| WO2021155262A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155264A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021231691A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi) |
| EP4150077A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1) |
| EP4150087A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
| WO2021231698A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
| EP4150090A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of otoferlin (otof) |
| EP4150086A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2) |
| EP4150088A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1) |
| EP4150076A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2) |
| WO2021236080A1 (en) | 2020-05-20 | 2021-11-25 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US11408000B2 (en) | 2020-06-03 | 2022-08-09 | Triplet Therapeutics, Inc. | Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity |
| KR20230050336A (ko) | 2020-07-10 | 2023-04-14 | 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) | 뇌전증을 치료하기 위한 방법과 조성물 |
| US12606553B2 (en) | 2021-03-09 | 2026-04-21 | Foghorn Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
| US20240263177A1 (en) | 2021-05-20 | 2024-08-08 | Korro Bio, Inc. | Methods and Compositions for Adar-Mediated Editing |
| WO2022256283A2 (en) | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Methods for restoring protein function using adar |
| US20230194709A9 (en) | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
| WO2023278410A1 (en) | 2021-06-29 | 2023-01-05 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
| KR102767089B1 (ko) * | 2021-09-07 | 2025-02-17 | 렉스소프트 주식회사 | 호흡기 질환 진단용 마커 및 이의 용도 |
| AU2022370009A1 (en) | 2021-10-22 | 2024-05-16 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
| WO2023122762A1 (en) | 2021-12-22 | 2023-06-29 | Camp4 Therapeutics Corporation | Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas |
| KR20250022763A (ko) | 2022-06-10 | 2025-02-17 | 캠프4 테라퓨틱스 코포레이션 | 조절 rna를 표적으로 하는 안티센스 올리고뉴클레오타이드를 사용하여 프로그래뉼린 발현을 조절하는 방법 |
| TW202426644A (zh) * | 2022-10-19 | 2024-07-01 | 美商亞羅生物治療公司 | Ｆｎ３域－ｓｉｒｎａ結合物及其用途 |
| EP4627084A1 (en) | 2022-12-01 | 2025-10-08 | Camp4 Therapeutics Corporation | Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas |
| EP4743577A1 (en) | 2023-07-13 | 2026-05-20 | Korro Bio, Inc. | RNA EDITING OLIGONUCLEOTIDES AND THEIR USES |
| AU2024287308A1 (en) | 2023-07-13 | 2025-12-18 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| WO2025080993A1 (en) * | 2023-10-13 | 2025-04-17 | Sri International | Altered immune mast cell therapy as a pre-exposure treatment of an allergic response |
| WO2025096809A1 (en) | 2023-10-31 | 2025-05-08 | Korro Bio, Inc. | Oligonucleotides comprising phosphoramidate internucleotide linkages |
| WO2025128799A1 (en) | 2023-12-12 | 2025-06-19 | Korro Bio, Inc. | Double-stranded rna-editing oligonucleotides and uses thereof |
| WO2025255388A1 (en) | 2024-06-05 | 2025-12-11 | Camp4 Therapeutics Corporation | Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas |
| WO2026050243A1 (en) | 2024-08-26 | 2026-03-05 | Korro Bio, Inc. | Galnac conjugated oligonucleotides for rna editing |
| WO2026122478A1 (en) | 2024-12-02 | 2026-06-11 | Korro Bio, Inc. | Extrahepatic delivery formulations and methods |
| WO2026124614A1 (en) | 2024-12-13 | 2026-06-18 | Nitrase Therapeutics, Inc. | Methods of treating disorders |
| WO2026136379A1 (en) | 2024-12-17 | 2026-06-25 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399754B1 (en) * | 1991-12-24 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides |
| US6005087A (en) * | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
| US5798340A (en) * | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5596091A (en) * | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
| FR2722506B1 (fr) * | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
| GB9510718D0 (en) * | 1995-05-26 | 1995-07-19 | Sod Conseils Rech Applic | Antisense oligonucleotides |
| US6013516A (en) * | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US6127533A (en) * | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
| WO1999060166A1 (en) * | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals, Inc. | Compositions and methods for the pulmonary delivery of nucleic acids |
| US6403779B1 (en) * | 1999-01-08 | 2002-06-11 | Isis Pharmaceuticals, Inc. | Regioselective synthesis of 2′-O-modified nucleosides |
| JP2003506074A (ja) * | 1999-08-09 | 2003-02-18 | ジェネッサンス ファーマシューティカルズ，インコーポレイティド | 薬剤標的同質遺伝子：免疫グロブリンｅ受容体ｉａｌｐｈａサブユニット遺伝子における多型 |
| WO2001048190A2 (en) * | 1999-12-23 | 2001-07-05 | Exiqon A/S | Therapeutic uses of lna-modified oligonucleotides |
| EP1386004A4 (en) * | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
| WO2002101071A2 (en) * | 2001-06-07 | 2002-12-19 | Rigel Pharmaceuticals, Inc. | Cd43:modulators of mast cell degranulation |
| WO2003010180A1 (en) * | 2001-07-23 | 2003-02-06 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for rnai mediated inhibition of gene expression in mammals |
| JP2005527639A (ja) * | 2001-11-02 | 2005-09-15 | インサート セラピューティクス インコーポレイテッド | Ｒｎａ干渉の治療的利用のための方法及び組成物 |
| US20030166018A1 (en) * | 2002-03-01 | 2003-09-04 | Matthias Wabl | Methods for identifying agents that modulate mast cell degranulation |
| WO2003079982A2 (en) * | 2002-03-19 | 2003-10-02 | Tularik Inc. | Gene amplification in cancer |
| WO2003099298A1 (en) * | 2002-05-24 | 2003-12-04 | Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
| US20040127395A1 (en) * | 2002-09-06 | 2004-07-01 | Desai Pragnya J. | Use of histamine H4 receptor modulators for the treatment of allergy and asthma |
| EP2305813A3 (en) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| AU2005214287A1 (en) * | 2004-02-20 | 2005-09-01 | Genesis Research And Development Corporation Limited | Targeted delivery of RNA interference molecules for the treatment of IgE-mediated disorders |
-
2005
- 2005-03-01 WO PCT/US2005/006445 patent/WO2005085443A2/en not_active Ceased
- 2005-03-01 US US11/069,611 patent/US20060058255A1/en not_active Abandoned
- 2005-03-01 EP EP05724064A patent/EP1737956A2/en not_active Withdrawn
- 2005-03-01 CA CA002558262A patent/CA2558262A1/en not_active Abandoned
- 2005-03-01 JP JP2007501881A patent/JP2007527240A/ja active Pending
-
2010
- 2010-09-27 US US12/891,626 patent/US20110112169A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6236498B2 (ja) | 非対称性干渉ｒｎａの組成物およびその使用 | |
| RU2656154C2 (ru) | СВЯЗАННАЯ С РЕСПИРАТОРНЫМ ЗАБОЛЕВАНИЕМ ГЕН-СПЕЦИФИЧЕСКАЯ миРНК, ДВУСПИРАЛЬНАЯ КОНСТРУКЦИЯ ОЛИГО-РНК, СОДЕРЖАЩАЯ миРНК, И СОДЕРЖАЩАЯ ЕЕ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ ЛЕЧЕНИЯ РЕСПИРАТОРНОГО ЗАБОЛЕВАНИЯ | |
| JP2022544412A5 (enExample) | ||
| US8669235B2 (en) | Modulation of innate immunity receptors' signaling by microRNAs miR-146a and miR-146b | |
| US20110112169A1 (en) | RNAi-BASED THERAPEUTICS FOR ALLERGIC RHINITIS AND ASTHMA | |
| US12037589B2 (en) | Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same | |
| JP2014097072A5 (enExample) | ||
| JP2010532163A5 (enExample) | ||
| JP2017512502A (ja) | 新規の二重らせんオリゴｒｎａおよびこれを含む線維症または呼吸器疾患の予防または治療用薬学組成物 | |
| Yao et al. | Nucleic acid nanomaterials-based therapy for osteoarthritis: Progress and prospects | |
| CN112143731A (zh) | 靶向破坏SARS-CoV-2病毒基因组的gRNA及其应用 | |
| Guan et al. | Efficiency and safety of five different agents for in vivo delivery of novel bioengineered RNAi molecules | |
| WO2022270071A1 (ja) | 肝線維化抑制のための剤及び医薬組成物 | |
| CA3101320C (en) | Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same | |
| Nally | Nanodelivery of MicroRNA Based Therapeutics to Macrophages | |
| EP4421173A1 (en) | Use of micrornas in the treatment of lung diseases | |
| US20240327830A1 (en) | Dise-inducing srna-polyplexes and srna-lipopolyplexes and methods of using the same to treat cancer | |
| US20230279393A1 (en) | Treatment of Airway Conditions by Modulation of MiR200 Family MicroRNAs | |
| HK40051564A (en) | Amphiregulin gene-specific double-stranded oligonucleotide and composition, for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same | |
| TW202545542A (zh) | 預防或治療流感的組成物及方法 | |
| WO2023215716A1 (en) | Compositions and methods for treatment of cancer | |
| CN121874194A (zh) | 一种靶向促皮肤瘢痕基因的siRNA及其应用 | |
| CN111228502A (zh) | 人ube2s基因的用途及相关产品 | |
| US20110152343A1 (en) | Protease inhibitors and broad-spectrum antiviral | |
| MXPA06009824A (en) | Rnai-based therapeutics for allergic rhinitis and asthma |